Ten beagle dogs were given omeprazole orally at a dose of 0.17 mg/kg (
0.5 mu mol/kg) daily for 7 years. Six dogs served as controls. Regular
ly evaluated criteria were clinical signs, body weight, food consumpti
on, rectal temperature, electrocardiography, hematology, blood chemist
ry, urinalysis, ophthalmoscopy, gastroscopic examination including gas
tric mucosal biopsy sampling for histological evaluation, pharmacokine
tics of omeprazole, and plasma gastrin levels. After approximately 5 y
ears, a quantitative gastric acid secretion test was performed. No tre
atment-related adverse clinical signs or effects were observed in the
dogs, and all animals survived to term. The annual gastroscopy with hi
stological examinations of gastric mucosa did not show any treatment-r
elated changes. At all investigations and in all dogs, the parietal ce
lls were morphologically normal, and there were no changes of pattern
or any increase in the number of argyrophil enterochromaffin-like cell
s compared to the control animals. In the plasma samples collected 24
h after dosing, there were no significant differences in either basal
or meal-stimulated gastrin levels between the controls and the omepraz
ole-treated animals. Peak plasma concentration of omeprazole occurred
within 2 h of dosing. The area under the concentration curve (AUC) was
not affected by dosing over 7 years and was in good agreement with th
e AUC in humans given a dose of 20 mg omeprazole daily. Acid secretion
tests after 5 years of treatment showed that the mean inhibition of a
cid secretion by omeprazole 4-7 h after dosing was as expected - about
50%. It is concluded that 7 years' treatment with omeprazole in dogs,
in a dose resulting in clinically relevant plasma concentrations, did
not cause any adverse effects in any of the animals. Furthermore, the
degree of acid inhibition of a submaximal dose of omeprazole is maint
ained during long-term treatment without any signs of tachyphylaxis.